Andreas U Monsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7990936/publications.pdf

Version: 2024-02-01

145 papers 8,851 citations

43 h-index 48315 88 g-index

174 all docs

174 docs citations

times ranked

174

12344 citing authors

#	Article	IF	CITATIONS
1	Comparisons of Verbal Fluency Tasks in the Detection of Dementia of the Alzheimer Type. Archives of Neurology, 1992, 49, 1253-1258.	4.5	606
2	Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. Age and Ageing, 2003, 32, 315-320.	1.6	574
3	DTI measures in crossing-fibre areas: Increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. NeuroImage, 2011, 55, 880-890.	4.2	468
4	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
5	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	375
6	A common brain network links development, aging, and vulnerability to disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17648-17653.	7.1	268
7	A comparison of category and letter fluency in Alzheimer's disease and Huntington's disease Neuropsychology, 1994, 8, 25-30.	1.3	251
8	Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgeryâ€"A randomized controlled trial*. Critical Care Medicine, 2009, 37, 1762-1768.	0.9	250
9	Episodic memory changes are associated with the APOE- epsilon 4 allele in nondemented older adults. Neurology, 1995, 45, 2203-2206.	1.1	238
10	Unawareness of Smell Loss in Normal Aging and Alzheimer's Disease: Discrepancy between Self-Reported and Diagnosed Smell Sensitivity. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 1995, 50B, P187-P192.	3.9	202
11	Evaluation of smartphoneâ€based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Movement Disorders, 2018, 33, 1287-1297.	3.9	196
12	A New Behavioral Assessment Scale for Geriatric Out―and Inâ€Patients: the NOSGER (Nurses' Observation) Tj E	ETQq0 0 0	rgBT/Overloo
13	Folstein vs Modified Mini-Mental State Examination in Geriatric Stroke. Archives of Neurology, 1995, 52, 477.	4.5	188
14	Clinical Validity of the Mattis Dementia Rating Scale in Detecting Dementia of the Alzheimer Type. Archives of Neurology, 1995, 52, 899.	4.5	168
15	Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 2147-2155.	3.6	161
16	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 989-999.	2.8	148
17	Preclinical cognitive markers of dementia of the Alzheimer type Neuropsychology, 1994, 8, 374-384.	1.3	127
18	Early Diagnosis of Dementia via a Two-Step Screening and Diagnostic Procedure. International Psychogeriatrics, 1997, 9, 123-130.	1.0	127

#	Article	lF	Citations
19	Neuropsychological studies of asymptomatic Human Immunodeficiency Virus-Type-1 infected individuals. Journal of the International Neuropsychological Society, 1995, 1, 304-315.	1.8	126
20	Modifiable and Nonmodifiable Risk Factors for Postoperative Delirium After Cardiac Surgery With Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2010, 24, 555-559.	1.3	118
21	Random number generation in dementia of the Alzheimer type: A test of frontal executive functions. Neuropsychologia, 1996, 34, 97-103.	1.6	113
22	Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1060-1063.	1.9	111
23	Improving the diagnostic accuracy of the Mini-Mental State Examination. Acta Neurologica Scandinavica, 1995, 92, 145-150.	2.1	92
24	Argyrophilic grain disease: distribution of grains in patients with and without dementia. Acta Neuropathologica, 1997, 94, 353-358.	7.7	84
25	Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 33-41.	3.1	84
26	Frontotemporal Dementia, Semantic Dementia, and Alzheimer's Disease: The Contribution of Standard Neuropsychological Tests to Differential Diagnosis. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 39-44.	2.3	83
27	Medial perirhinal cortex disambiguates confusable objects. Brain, 2012, 135, 3757-3769.	7.6	83
28	The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 322-334.	1.3	81
29	Screening for dementia of the alzheimer type in the community: The utility of the clock drawing test. Archives of Clinical Neuropsychology, 1996, 11, 529-539.	0.5	79
30	Early detection of Alzheimer's disease with a total score of the German CERAD. Journal of the International Neuropsychological Society, 2010, 16, 910-920.	1.8	79
31	The 12 Years Preceding Mild Cognitive Impairment Due to Alzheimer's Disease: The Temporal Emergence of Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, 1095-1107.	2.6	79
32	The Montreal Cognitive Assessment: Normative Data from a German-Speaking Cohort and Comparison with International Normative Samples. Journal of Alzheimer's Disease, 2018, 64, 643-655.	2.6	74
33	Distinct neuroanatomical bases of episodic and semantic memory performance in Alzheimer's disease. Neuropsychologia, 2013, 51, 930-937.	1.6	72
34	Safety and Effectiveness of Low-Dose Clozapine in Psychogeriatric Patients: A Preliminary Study. International Psychogeriatrics, 1992, 4, 187-195.	1.0	68
35	Screening properties of the German IQCODE with a two-year time frame in MCI and early Alzheimer's disease. International Psychogeriatrics, 2010, 22, 91-100.	1.0	60
36	Discrimination of cortical from subcortical dementias on the basis of memory and problem-solving tests. Journal of Clinical Psychology, 1995, 51, 48-58.	1.9	59

#	Article	IF	Citations
37	Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nature Clinical Practice Neurology, 2008, 4, 226-232.	2.5	57
38	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
39	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 537-547.	10.2	55
40	Lack of Practice Effects on Neuropsychological Tests as Early Cognitive Markers of Alzheimer Disease?. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 416-426.	1.9	50
41	Silent brain infarcts impact on cognitive function in atrial fibrillation. European Heart Journal, 2022, 43, 2127-2135.	2.2	50
42	Slowing of EEG Background Activity in Parkinsonââ,¬â,,¢s and Alzheimerââ,¬â,,¢s Disease with Early Cognitive Dysfunction. Frontiers in Aging Neuroscience, 2014, 6, 314.	3.4	49
43	Cortical thinning of parahippocampal subregions in very early Alzheimer's disease. Neurobiology of Aging, 2016, 38, 188-196.	3.1	49
44	Associations Between Impaired Cerebral Blood Flow Autoregulation, Cerebral Oxygenation, and Biomarkers of Brain Injury and Postoperative Cognitive Dysfunction in Elderly Patients After Major Noncardiac Surgery. Anesthesia and Analgesia, 2017, 124, 934-942.	2.2	49
45	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 153-166.	3.1	49
46	Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment. Alzheimer's Research and Therapy, 2020, 12, 39.	6.2	49
47	Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Medical Weekly, 2017, 147, w14467.	1.6	46
48	Utility of a modified version of the wisconsin card sorting test in the detection of dementia of the alzheimer type. Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist, 1993, 7, 161-170.	1.2	44
49	Impact of APOE status on cognitive maintenance in healthy elderly persons. International Journal of Geriatric Psychiatry, 2009, 24, 132-141.	2.7	44
50	Neuropsychological Signs of Alzheimer's Disease 8 Years Prior to Diagnosis. Journal of Alzheimer's Disease, 2013, 34, 537-546.	2.6	43
51	Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). European Archives of Psychiatry and Clinical Neuroscience. 2015. 265. 407-417.	3.2	43
52	Evaluation of diagnostic scores with adjustment for covariates. Statistics in Medicine, 2008, 27, 1777-1790.	1.6	40
53	The Barrow Neurological Institute Grading Scale as a Predictor for Delayed Cerebral Ischemia and Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From a Nationwide Patient Registry (Swiss) Tj ETQq1	1.0.7843	1 4 9rgBT /O
54	Microstate connectivity alterations in patients with early Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 78.	6.2	38

#	Article	IF	Citations
55	Weight change and cognitive performance. International Journal of Obesity, 2004, 28, 1163-1167.	3.4	37
56	Serial position effects are sensitive predictors of conversion from MCI to Alzheimer's disease dementia. Alzheimer's and Dementia, 2014, 10, S420-4.	0.8	36
57	An exploration of cognitive subgroups in Alzheimer's disease. Journal of the International Neuropsychological Society, 2010, 16, 233-243.	1.8	35
58	Call for uniform neuropsychological assessment after aneurysmal subarachnoid hemorrhage: Swiss recommendations. Acta Neurochirurgica, 2015, 157, 1449-1458.	1.7	35
59	Norms for change in episodic memory as a prerequisite for the diagnosis of mild cognitive impairment (MCI) Neuropsychology, 2009, 23, 189-200.	1.3	33
60	Comparison of Verbal Episodic Memory Measures: Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT). Archives of Clinical Neuropsychology, 2012, 27, 510-519.	0.5	33
61	CSF-Tau and CSF-Aβ _{1–42} in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2010, 29, 530-533.	1.5	31
62	Category fluency is also predominantly affected in Swiss Alzheimer's disease patients. Acta Neurologica Scandinavica, 1997, 95, 81-84.	2.1	29
63	Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1106-1112.	3.0	29
64	Human Activity Recognition from Sensor-Based Large-Scale Continuous Monitoring of Parkinson's Disease Patients. , 2017, , .		28
65	Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimer's Research and Therapy, 2012, 4, 51.	6.2	27
66	Serum Anticholinergic Activity and Postoperative Cognitive Dysfunction in Elderly Patients. Anesthesia and Analgesia, 2014, 119, 947-955.	2.2	27
67	Global N-Acetylaspartate in Normal Subjects, Mild Cognitive Impairment and Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2014, 43, 939-947.	2.6	27
68	Apolipoprotein E allele frequencies in argyrophilic grain disease. Acta Neuropathologica, 1998, 96, 225-227.	7.7	26
69	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience and Therapeutics, 2010, 16, 246-253.	3.9	25
70	Whole brain N-acetylaspartate concentration is conserved throughout normal aging. Neurobiology of Aging, 2012, 33, 2440-2447.	3.1	25
71	Current practice in neuropsychological outcome reporting after aneurysmal subarachnoid haemorrhage. Acta Neurochirurgica, 2013, 155, 2045-2051.	1.7	25
72	Neuropsychological Markers of Medial Perirhinal and Entorhinal Cortex Functioning are Impaired Twelve Years Preceding Diagnosis of Alzheimer's Dementia. Journal of Alzheimer's Disease, 2016, 52, 573-580.	2.6	24

#	Article	IF	CITATIONS
73	The Neurocognitive Assessment in the Metabolic and Aging Cohort (<scp>NAMACO</scp>) study: baseline participant profile. HIV Medicine, 2020, 21, 30-42.	2.2	24
74	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
75	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
76	Becoming Forgetful: How Elderly People Deal With Forgetfulness in Everyday Life. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 347-353.	1.9	23
77	General practitioners' attitudes towards early diagnosis of dementia: a cross-sectional survey. BMC Family Practice, 2019, 20, 65.	2.9	23
78	Facial Emotion Recognition Performance Differentiates Between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. Journal of Clinical Psychiatry, 2018, 79, 16m11342.	2.2	22
79	Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's disease. Clinical Neurophysiology, 2013, 124, 2146-2152.	1.5	21
80	Head Motion Parameters in fMRI Differ Between Patients with Mild Cognitive Impairment and Alzheimer Disease Versus Elderly Control Subjects. Brain Topography, 2014, 27, 801-807.	1.8	21
81	Varying Strength of Cognitive Markers and Biomarkers to Predict Conversion and Cognitive Decline in an Early-Stage-Enriched Mild Cognitive Impairment Sample. Journal of Alzheimer's Disease, 2015, 44, 625-633.	2.6	21
82	Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study. Aging Clinical and Experimental Research, 2017, 29, 609-619.	2.9	21
83	Screening for dementia of the alzheimer type in the community: The utility of the clock drawing test. Archives of Clinical Neuropsychology, 1996, 11, 529-539.	0.5	20
84	Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Current Medical Research and Opinion, 2004, 20, 931-938.	1.9	20
85	Classification of Alzheimer's Disease from structural MRI using sparse logistic regression with optional spatial regularization., 2011, 2011, 4499-502.		20
86	Establishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression. International Journal of Geriatric Psychiatry, 2014, 29, 624-634.	2.7	20
87	BrainCheck - a very brief tool to detect incipient cognitive decline: optimized case-finding combining patient- and informant-based data. Alzheimer's Research and Therapy, 2014, 6, 69.	6.2	20
88	Age-dependent effects of the 5-hydroxytryptamine-2a-receptor polymorphism (His452Tyr) on human memory. NeuroReport, 2005, 16, 839-842.	1.2	19
89	Argyrophilic Grain Disease. Advances in Experimental Medicine and Biology, 2001, , 39-58.	1.6	19
90	Specific care program for the older adults: Memory Clinics. European Geriatric Medicine, 2010, 1, 128-131.	2.8	18

#	Article	IF	Citations
91	Argyrophilic grain disease: molecular genetic difference to other four-repeat tauopathies. Acta Neuropathologica, 2003, 106, 363-366.	7.7	17
92	Clinical EEG in cognitively impaired patients with Parkinson's Disease. Journal of the Neurological Sciences, 2011, 310, 75-78.	0.6	17
93	Efficacy of Donepezil Treatment in Alzheimer Patients with and without Subcortical Vascular Lesions. Pharmacology, 2004, 72, 1-5.	2.2	16
94	No association of a non-synonymous PLAU polymorphism with Alzheimer's disease and disease-related traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 21-23.	1.7	16
95	Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. Acta Neuropathologica Communications, 2019, 7, 72.	5.2	16
96	Older Candidates for Subthalamic Deep Brain Stimulation in Parkinson's Disease Have a Higher Incidence of Psychiatric Serious Adverse Events. Frontiers in Aging Neuroscience, 2016, 8, 132.	3.4	15
97	Semantic and phonemic sequence effects in random word generation: A dissociation between Alzheimer's and Huntington's disease patients. Journal of the International Neuropsychological Society, 2005, 11, 303-310.	1.8	14
98	Clinical Characteristics of Dementia Associated with Argyrophilic Grain Disease. Dementia and Geriatric Cognitive Disorders, 2007, 24, 229-234.	1.5	14
99	For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimer's Research and Therapy, 2011, 3, 9.	6.2	14
100	False positives to confusable objects predict medial temporal lobe atrophy. Hippocampus, 2013, 23, 832-841.	1.9	14
101	A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 635-641.	2.5	14
102	How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, wellâ€treated HIVâ€positive population?. HIV Medicine, 2020, 21, 342-348.	2.2	14
103	Global brain volume and N-acetyl-aspartate decline over seven decades of normal aging. Neurobiology of Aging, 2021, 98, 42-51.	3.1	14
104	Assessment of dementia in elderly outpatients: a comparative study of European centers and consensus statement. Archives of Gerontology and Geriatrics, 2000, 30, 17-24.	3.0	12
105	Topographical recognition memory sensitive to amnestic mild cognitive impairment but not to depression. International Journal of Geriatric Psychiatry, 2006, 21, 924-929.	2.7	12
106	Evaluation of a Summary Score of Cognitive Performance for Use in Trials in Perioperative and Critical Care. Dementia and Geriatric Cognitive Disorders, 2011, 31, 451-459.	1.5	11
107	Distinct neural systems underlying reduced emotional enhancement for positive and negative stimuli in early Alzheimer's disease. Frontiers in Human Neuroscience, 2013, 7, 939.	2.0	11
108	Dissociation in Rating Negative Facial Emotions between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2016, 24, 1017-1027.	1.2	11

#	Article	IF	CITATIONS
109	Measuring the Impact of Delayed Cerebral Ischemia on Neuropsychological Outcome After Aneurysmal Subarachnoid Hemorrhage—Protocol of a Swiss Nationwide Observational Study (MoCA–DCI Study). Neurosurgery, 2019, 84, 1124-1132.	1.1	11
110	Biomarkers of dementia: Comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods, 2012, 56, 494-499.	3.8	10
111	Assessment of everyday behavior in Alzheimer's disease patients: Its significance for diagnostics and prediction of disease progression. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 151-158.	1.9	9
112	TOMMORROW neuropsychological battery: German language validation and normative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 314-323.	3.7	9
113	Blood Pressure and Brain Lesions in Patients With Atrial Fibrillation. Hypertension, 2021, 77, 662-671.	2.7	8
114	Early diagnosis and management of dementia in general practice – how do Swiss GPs meet the challenge?. Swiss Medical Weekly, 2018, 148, w14695.	1.6	8
115	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. Heart Rhythm, 2021, 18, 512-519.	0.7	7
116	Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets. Alzheimer's Research and Therapy, 2021, 13, 97.	6.2	7
117	The whole-brain N-acetylaspartate correlates with education in normal adults. Psychiatry Research - Neuroimaging, 2012, 204, 49-54.	1.8	6
118	A short tool to screen HIV-infected patients for mild neurocognitive disorders – a pilot study. BMC Psychology, 2014, 2, 21.	2.1	6
119	A longitudinal linguistic analysis of written text production in a case of semantic variant primary progressive aphasia. Journal of Neurolinguistics, 2016, 39, 26-37.	1.1	6
120	Parietal lobe critically supports successful paired immediate and single-item delayed memory for targets. Neurobiology of Learning and Memory, 2017, 141, 53-59.	1.9	6
121	Smartphone-based continuous mobility monitoring of Parkinsons disease patients reveals impacts of ambulatory bout length on gait features. , 2017, , .		6
122	Large-Scale Continuous Mobility Monitoring of Parkinson's Disease Patients Using Smartphones. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2018, , 12-19.	0.3	6
123	Apolipoprotein E3Basel: new insights into a highly conserved protein region. European Journal of Clinical Investigation, 2003, 33, 677-685.	3.4	5
124	Turning principles into practice in Alzheimer's disease. International Journal of Clinical Practice, 2010, 64, 1198-1209.	1.7	5
125	"Now I see it, now I don't― Determining Threshold Levels of Facial Emotion Recognition for Use in Patient Populations. Journal of the International Neuropsychological Society, 2015, 21, 568-572.	1.8	5
126	A factor score reflecting cognitive functioning in patients from the Swiss Atrial Fibrillation Cohort Study (Swiss-AF). PLoS ONE, 2020, 15, e0240167.	2.5	5

#	Article	IF	CITATIONS
127	Use it or lose it! Cognitive activity as a protec-tive factor for cognitive decline associated with Alzheimer's disease. Swiss Medical Weekly, 2017, 147, w14407.	1.6	5
128	Cats and Apples: Semantic Fluency Performance for Living Things Identifies Patients with Very Early Alzheimer's Disease. Archives of Clinical Neuropsychology, 2021, 36, 838-843.	0.5	5
129	Long-term risk of adverse outcomes according to atrial fibrillation type. Scientific Reports, 2022, 12, 2208.	3.3	5
130	O1-06-01: Challenges in international clinical trials to delay early symptomatic Alzheimer's disease. , 2013, 9, P137-P138.		4
131	Decision-making capacity evaluations: the role of neuropsychological assessment from a multidisciplinary perspective. BMC Geriatrics, 2020, 20, 535.	2.7	4
132	Association between changes in cerebral grey matter volume and postoperative cognitive dysfunction in elderly patients: study protocol for a prospective observational cohort study. BMC Anesthesiology, 2016, 16, 118.	1.8	3
133	Genome-wide Association Study of Postoperative Cognitive Dysfunction in Older Surgical Patients. Journal of Neurosurgical Anesthesiology, 2022, 34, 248-250.	1.2	3
134	The Basel Version of the Awareness of Social Inference Test-Emotion Recognition (BASIT-ER): Preliminary validation analyses in healthy adults Neuropsychology, 2022, 36, 175-184.	1.3	3
135	Answer to "Social cognition assessment for mild neurocognitive disorders― Alzheimer's and Dementia, 2022, 18, 1441-1442.	0.8	3
136	The Verbal Fluency Decline After Deep Brain Stimulation in Parkinson's Disease: Is There an Influence of Age?. Movement Disorders Clinical Practice, 2016, 3, 48-52.	1.5	2
137	A Comparison of Serial Position Effects in Patients with Mild Cognitive Impairment due to Parkinson's Disease or to Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2020, 49, 170-178.	1.5	1
138	Predictive value of serum neurofilament light chain for persistent cognitive deficits in elderly depressive patients. Journal of Affective Disorders Reports, 2021, 4, 100095.	1.7	1
139	Weight History over a Forty-Year Time Period. International Journal for Vitamin and Nutrition Research, 2005, 75, 290-296.	1.5	O
140	[P2–300]: CORTICAL THICKNESS OF MEDIAL PERIRHINAL CORTEX PREDICTS VERBAL SEMANTIC FLUENCY PERFORMANCE FOR LIVING THINGS. Alzheimer's and Dementia, 2017, 13, P731.	0.8	0
141	P3â€489: GERMAN NORMATIVE DATA FOR THE MONTREAL COGNITIVE ASSESSMENT. Alzheimer's and Dementia, 2018, 14, P1309.	0.8	O
142	The context effect in facial emotion perception increases with age. Alzheimer's and Dementia, 2020, 16, e040309.	0.8	0
143	Position Statement on Anti-Dementia Medication for Alzheimer's Disease by Swiss Stakeholders. Clinical and Translational Neuroscience, 2021, 5, 14.	0.9	O
144	Diagnosing foreign patients in Europe: An EADCâ€ISTAART study. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	CITATIONS
145	Novel oddity detection task differentiates early Alzheimer's disease and major depression. Alzheimer's and Dementia, 2021, 17, .	0.8	O